Board of Directors

Diana has more than 20 years of experience in the biopharmaceutical industry and academic medicine and has authored more than 200 publications. She currently serves as chief executive officer of AlloVir, where she also sits on the board of directors. Previously, Diana spent more than a decade at Gilead Sciences, where she served as head of the virology therapeutic area and oversaw the development and launch of the hepatitis C treatments Sovaldi® (sofosbuvir), Harvoni® (ledipasvir/sofosbuvir), and Epclusa® (sofosbuvir and velpatasvir) and the HIV treatment Biktarvy® (bictegravir, emtricitabine & tenofovir alafenamide). In 2020, Diana led Gilead’s initiative to rapidly advance Veklury® (remdesivir), earning her global recognition as one of the most influential people in the fight against COVID-19. She began her career in the biopharma industry at Merck & Co. where she held positions in clinical pharmacology and experimental medicine. She is also currently on the board of Nektar Therapeutics. Diana received an M.D. from Tulane University School of Medicine and a B.A. in comparative literature from Brown University. Following completion of her medical training, she was on the faculty at Harvard Medical School where her NIH-funded research focused on HIV immunology and T-cell trafficking.